Wantstats
Company ProfilePremium

Echosens

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Echosens - Healthcare showcase

Year Founded & Workforce

2001

9,000 Employees

Industry

Healthcare

Services

Non-Invasive TechnologyBlood Test
E

Echosens Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Echosens Overview

Company Headquarters: Paris, France

Founded: 2001

Workforce: ~9000 (2018)

Company Working: Echosens develops, manufactures, and markets non-invasive diagnostic products and services in the field of hepatology. The company offers FibroScan, which is based on proprietary vibration controlled transient elastography technology and is used in routine clinical practice and research; FibroMeter range that provides blood tests; and FibroView, which offers smart connectivity software solutions linking FibroScan to the hospital information systems. Echosens currently possesses more than 22 patent families. The company has six subsidiaries in Germany, Hong Kong, Spain, China, Lebanon, and the US.

Strategy

Echosens aims to become the leading company for non-invasive diagnostic in hepatology globally. The company continuously strives to help improve the quality of life for patients by expanding its product portfolio. Moreover, the company aims to provide its product FibroScan with proprietary VCTE technology to most of the regional hospitals and clinics through joint ventures to brace its position in the market.

Company Snapshot

9,000

Employees

2001

Founded

Paris, France

Headquarters

SWOT Analysis

Strengths

  • Specialized in non-invasive liver diagnosis
  • Efficient distribution network
  • Extensive R&D capabilities

Weaknesses

  • Limited products
  • Focus limited to major markets of Europe and US

Opportunities

  • Mergers & acquisitions

Threats

  • Currency fluctuations

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
February 2019CollaborationEchosens announced a pilot study in collaboration with the NASH Network designed to appropriately identify patients with the progressive non-alcoholic fatty liver disease using FibroScan. The study will utilize FibroScan in conjunction with routine lab tests, lipidomic and metabolic profiles, magnetic resonance elastography (MRE), exploratory biomarkers, and morphometric analysis. Through this collaboration, the company aims to expand its customer base and increase its market penetration.

Product Offering

  • Echosens
    • Non-Invasive Technology
    • Blood Test

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →